Clinical trials: Metastatic Disease
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Secondary Hypogonadism
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.
- Trial name
- NCT00706719
- Testing
- 25 mg Androxal, Testim 1%
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Repros Therapeutics Inc.
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12…
- Trial name
- NCT01461044
- Where
- 82 sites in France
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.
- Trial name
- NCT00984464
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Gastrointestinal Stromal Tumor
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
- Trial name
- NCT01039519
- Testing
- Ganetespib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Synta Pharmaceuticals Corp.
Metastatic Breast Cancer
Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines
This is an open, multicentre, prospective observational (non-interventional) study, performed in Belgium. Principal objectives: 1.
- Trial name
- NCT01555944
- Where
- 24 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Teva Pharma
Chronic Lymphocytic Leukemia
Acalabrutinib Real World Italian obSErvational Study -ARISE
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the adults in the Western world, with an annual incidence of approximately 5 cases per 100,000 inhabitants in Italy.
- Trial name
- ARISE (NCT06205498)
- Testing
- acalabrutinib
- Where
- 41 sites in Italy
- Volunteers
- 151 people
- Sponsor
- AstraZeneca
Solid Tumor (Phase I), RAS Mutation
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5…
- Conditions
- Solid Tumor (Phase I), RAS Mutation, CEACAM5
- Trial name
- NCT07686445
- Testing
- Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor.
- Where
- 2 sites in Australia
- Volunteers
- 228 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Melanoma
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
- Trial name
- NCT01009775
- Testing
- YM155, Docetaxel
- Where
- 13 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
Urothelial Carcinoma
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options.
- Trial name
- NCT05562830
- Testing
- Zilovertamab vedotin, Pembrolizumab, MK-3120
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Colorectal Cancer
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial.
- Conditions
- Breast Cancer, Colorectal Cancer, Metastases
- Trial name
- NCT00096967
- Testing
- Avastin (bevacizumab)
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06989671
- Testing
- JMT101, SYS6002, SG001
- Volunteers
- 430 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Malignant Melanoma
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received…
- Trial name
- NCT00864253
- Testing
- ABI-007, Dacarbazine
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 529 people
- Sponsor
- Celgene
Neoplasms
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
The primary purpose of this study is to identify a dose of Liposome Entrapped c-raf Antisense Oligonucleotide Easy-to-Use (LErafAON-ETU) which maximizes potential benefits of the compound to patients with advanced cancer, without…
- Trial name
- NCT00100672
- Testing
- LErafAON-ETU
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Melanoma
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells.
- Trial name
- NCT00522834
- Testing
- Elesclomol (STA-4783), Paclitaxel
- Where
- 101 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Synta Pharmaceuticals Corp.
Metastatic Pancreatic Adenocarcinoma
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
- Trial name
- NCT01233375
- Testing
- CO-1.01
- Where
- 13 sites in United States
- Volunteers
- 19 people
- Sponsor
- Clovis Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.